Form 4: Director Kaye Foster-Cheek Reports Changes in Beneficial Ownership of Agios Pharmaceuticals Stock

Kaye Foster-Cheek, a director of Agios Pharmaceuticals, reports the vesting of restricted stock units, a gift of shares to a non-profit, and transactions affecting her beneficial ownership of the company's common stock.

Summary

• On June 13, 2024, Kaye Foster-Cheek, a director of Agios Pharmaceuticals, engaged in transactions involving the company's common stock.
• These transactions included the vesting of 3,388 restricted stock units, each representing a contingent right to receive one share of Agios' common stock.
• Foster-Cheek also gifted 3,564 shares to a not-for-profit organization.
• Following these transactions, Foster-Cheek directly owns 5,348 shares of Agios Pharmaceuticals and indirectly owns 2,200 shares through the Foster Family Revocable Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions and provides insight into the holdings of a key company director. It doesn't necessarily reflect broader industry trends but offers transparency into individual executive actions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly altering the ownership structure of the company.
• The gift of shares to a non-profit could be viewed positively from a corporate social responsibility perspective.

Key Dates